ABSK 043
Alternative Names: ABSK-043Latest Information Update: 05 Dec 2023
At a glance
- Originator Abbisko Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Cancer
Most Recent Events
- 20 Oct 2023 Efficacy, pharmacodynamics and adverse events data from a phase I trial in Solid tumors presented at the 48th European Society for Medical Oncology Congress 2023 (ESMO-2023)
- 16 Oct 2023 Pharmacodynamics and adverse event data from a phase I/IIa trial in Solid tumours released by Abbisko Therapeutics
- 27 Apr 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, In adults, In the elderly, Monotherapy) in Australia (PO) (NCT04964375)